<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093377</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol Version 6.0</org_study_id>
    <nct_id>NCT02093377</nct_id>
  </id_info>
  <brief_title>ASV for Sleep Apnea After Myocardial Infarction</brief_title>
  <acronym>TEAM ASV-I</acronym>
  <official_title>Treatment of Sleep Apnea Early After Myocardial Infarction With Adaptive Servo-Ventilation - a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ResMed Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Regensburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized controlled trial is to test the effect of 12 weeks Adaptive
      Servo-Ventilation (ASV) therapy (additionally to optimal medical management of myocardial
      infarction) on myocardial salvage (MSI=myocardial salvage/area at risk, primary endpoint).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Outcome Measure: myocardial salvage index, MSI

      - To test the effect of 12 weeks of ASV (additionally to percutaneous coronary intervention,
      PCI, and optimal medical management of AMI) on myocardial salvage (myocardial salvage index,
      MSI, assessed by cardiovascular magnetic resonance imaging, CMR).

      Secondary Outcome Measures:

      - To test whether ASV therapy in patients with SA early after AMI decreases infarct size and
      improves left ventricular remodelling (myocardial salvage, microvascular obstruction change
      of infarct size, infarct size at 12 weeks, change of left ventricular ejection fraction
      (LVEF), left ventricular systolic volume (LVSV), left ventricular diastolic volume (LVDV) and
      LVEF at 12 weeks; assessed with CMR).

      B-type natriuretic peptide (NT-proBNP)

        -  To test whether ASV therapy in patients with SA early after AMIimproves disease specific
           symptom burden (Seattle Angina Questionnaire)

        -  To test whether ASV therapy in patients with sleep apnea early after AMI suppresses
           sleep apnea (apneas and hypopneas/hour of sleep, mean oxygen saturation).

        -  To test whether ASV therapy in patients with sleep apnea early after AMI increases renal
           function (Glomerular Filtration Rate, calculated using the 4vMDRD formula).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>myocardial salvage index, MSI</measure>
    <time_frame>12 weeks</time_frame>
    <description>To test the effect of 12 weeks of ASV (additionally to percutaneous coronary intervention, PCI, and optimal medical management of AMI) on myocardial salvage (myocardial salvage index, MSI, assessed by cardiovascular magnetic resonance imaging, CMR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>infarct size and left ventricular remodelling</measure>
    <time_frame>12 weeks</time_frame>
    <description>To test whether ASV therapy in patients with SA early after AMI decreases infarct size and improves left ventricular remodelling (myocardial salvage, microvascular obstruction change of infarct size, infarct size at 12 weeks, change of left ventricular ejection fraction (LVEF), left ventricular systolic volume (LVSV), left ventricular diastolic volume (LVDV) and LVEF at 12 weeks; assessed with CMR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-type natriuretic peptide (NT-proBNP)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To test whether ASV therapy in patients with SA early after AMI reduces B-type natriuretic peptide (NT-proBNP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease specific symptom burden</measure>
    <time_frame>12 weeks</time_frame>
    <description>To test whether ASV therapy in patients with SA early after AMIimproves disease specific symptom burden (Seattle Angina Questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>suppresses sleep apnea</measure>
    <time_frame>12 weeks</time_frame>
    <description>To test whether ASV therapy in patients with sleep apnea early after AMI suppresses sleep apnea (apneas and hypopneas/hour of sleep, mean oxygen saturation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>12 weeks</time_frame>
    <description>increases renal function (Glomerular Filtration Rate, calculated using the 4vMDRD formula).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adaptive servo-ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology plus treatment of sleep apnea with adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia). Dose: The optimal ASV settings will be determined during 1-2 nights monitored by polygraphy within 5 days after PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Adaptive servo-ventilation</intervention_name>
    <description>Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)</description>
    <arm_group_label>Adaptive servo-ventilation</arm_group_label>
    <other_name>ASV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 18-80 years

          2. first AMI (ST-elevation in ECG or acute occlusion of coronary artery)

          3. Primary successful PCI achieved &lt;24 h after symptom onset

          4. SA with an AHI &gt;=15 per hour recording time

          5. written informed consent

        Exclusion criteria:

          1. previous myocardial infarction

          2. previous myocardial revascularization (PCI or surgical)

          3. LVEF &lt;45% and central sleep apnea

          4. indication for a surgical revascularisation

          5. cardiogenic shock, mean supine blood pressure &lt;60mmHg or NYHA class IV

          6. implanted cardiac device or other contraindications for CMR

          7. known allergies or other contraindication to contrast medium (e.g.
             GFR&lt;30ml/min/1.73m²)

          8. history of stroke

          9. contraindications for positive airway pressure support (hypotension with mean supine
             BP &lt;60mmHg, dehydration, inability to clear secretions, patients at risk for
             aspiration of gastric contents, severe bullous lung disease, history of pneumothorax
             and/or pneumomediastinum, a history of epistaxis, causing pulmonary aspiration of
             blood, cerebrospinal fluid leak or recent skull operations or injury) patients on or
             with indication for oxygen therapy, mechanical/non-invasive ventilation

         10. patients on nocturnal positive airway pressure support

         11. severe obstructive or restrictive airway disease

         12. heart failure due to primary valve disease

         13. patients awaiting heart transplantation

         14. diurnal symptoms of OSA requiring immediate treatment

         15. pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Arzt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Regensburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Arzt, MD</last_name>
    <phone>+49 941 944 7281</phone>
    <email>michael.arzt@ukr.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Dreher, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Dreher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaf Oldenburg, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olaf Oldenburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonhard Bruch, MD</last_name>
    </contact>
    <investigator>
      <last_name>Leonhard Bruch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Meyer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sven Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Arzt, MD</last_name>
      <phone>+49 941 944 7281</phone>
      <email>michael.arzt@ukr.de</email>
    </contact>
    <investigator>
      <last_name>Michael Arzt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Buchner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kurt Debl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Hetzenecker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2014</study_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Regensburg</investigator_affiliation>
    <investigator_full_name>Michael Arzt</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>acute myocardial infarction</keyword>
  <keyword>sleep apnea</keyword>
  <keyword>adaptive servo-ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

